---
layout: default
title: Dapagliflozin
parent: 僅模型預測 (L5)
nav_order: 158
evidence_level: L5
indication_count: 0
---

# Dapagliflozin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dapagliflozin: Evidence Pack Assessment — No Predicted New Indications Available

## One-Sentence Summary

Dapagliflozin (DrugBank: DB06292) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor widely used internationally for type 2 diabetes mellitus, heart failure, and chronic kidney disease. The current Evidence Pack contains **no TxGNN-predicted new indications**, and the drug shows **0 SAHPRA registrations** in the provided dataset, resulting in insufficient data to evaluate any repurposing candidates at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in evidence pack (internationally: type 2 diabetes mellitus) |
| Predicted New Indication | **None** — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| South Africa Market Status | Not marketed (per evidence pack) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

**No TxGNN predictions were generated for Dapagliflozin in this evidence pack.** Therefore, no mechanistic plausibility assessment can be performed for a new indication.

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, Dapagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. It works by blocking glucose reabsorption in the proximal renal tubule, leading to urinary glucose excretion (glycosuria), thereby lowering blood glucose levels. Beyond glycaemic control, SGLT2 inhibitors have demonstrated significant cardiorenal protective effects, which have led to approved indications for heart failure (with reduced and preserved ejection fraction) and chronic kidney disease in multiple regulatory jurisdictions worldwide.

The absence of TxGNN predictions may be due to incomplete data ingestion (no original indications were mapped in the evidence pack) or the drug not being present in the local regulatory dataset. This does **not** imply that Dapagliflozin lacks repurposing potential — rather, the analytical pipeline did not generate outputs for evaluation.

---

## Clinical Trial Evidence

Currently no TxGNN-predicted indication is available; therefore, no targeted clinical trial search was performed.

---

## Literature Evidence

Currently no TxGNN-predicted indication is available; therefore, no targeted literature search was performed.

---

## South Africa Market Information

The evidence pack reports **0 SAHPRA registrations** and a market status of "Not marketed."

> **Note:** This may reflect a data gap rather than actual market absence. Healthcare professionals should verify current SAHPRA registration status directly via the SAHPRA database, as Dapagliflozin (brand name Forxiga®, AstraZeneca) is registered and marketed in many countries globally. If the drug is indeed available in South Africa under a different data source not captured by this pipeline, the evidence pack should be updated accordingly.

---

## Safety Considerations

> Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

No safety data (warnings, contraindications, or drug-drug interactions) was available in the evidence pack. All safety fields returned as data gaps.

---

## Data Gaps Identified

The following critical data gaps were flagged in this evidence pack:

| Gap ID | Category | Item | Severity | Impact | Remediation |
|--------|----------|------|----------|--------|-------------|
| DG001 | Drug Level | SAHPRA PI warnings/contraindications | **Blocking** | Cannot enter Stage 1 safety screening | Download and parse PI PDF from SAHPRA |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Affects mechanistic relevance analysis | Query DrugBank API |

Additionally, the following structural gaps are noted:
- **Original indications**: Empty — no approved indications were mapped from the local regulatory data
- **Predicted indications**: Empty — TxGNN model produced no predictions, likely due to missing input data
- **SAHPRA registrations**: Zero — requires verification against current SAHPRA database

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack is substantially incomplete — no original indications were mapped, no TxGNN predictions were generated, and no safety data is available. Without a predicted new indication, no repurposing evaluation can be conducted. The blocking data gap (DG001) further prevents any safety screening.

**To proceed, the following is needed:**
- Verify SAHPRA registration status for Dapagliflozin (Forxiga®) directly from the SAHPRA database and update the evidence pack
- Resolve DG001: Obtain the SAHPRA-approved Professional Information (PI) for safety data extraction
- Resolve DG002: Query DrugBank API for detailed mechanism of action data
- Re-run the TxGNN prediction pipeline once original indications and DrugBank mapping are correctly populated
- Ensure the drug's approved indications (type 2 diabetes, heart failure, chronic kidney disease) are properly mapped into the knowledge graph before prediction

---

*Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. All predictions must be verified through rigorous clinical trials.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

